NeuroVision Imaging Inc. has acquired Durin Life Sciences Inc., combining blood-based biomarker diagnostics with retinal imaging and a national telehealth platform to create an integrated solution for earlier detection and management of neurodegenerative diseases. The combined company will operate under the NeuroVision name and continue to be led by Steven Verdooner, CEO and co-founder of NeuroVision. Financial terms were not disclosed.
Durin Life Sciences developed Duritect™, a suite of blood-based diagnostic tests designed for early detection and monitoring of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related disorders, often years before symptoms appear. NeuroVision contributes its BrainHealth.net platform, which delivers telehealth-enabled cognitive assessments, care navigation and longitudinal brain health programs across the United States, along with its retinal imaging technology.
The transaction creates a comprehensive platform pairing advanced diagnostics with scalable clinical and patient engagement capabilities. Ric Edelman, majority owner of Durin, will join the board of the combined company. The deal aims to accelerate the commercialization of noninvasive tools that support earlier intervention and ongoing care for patients at risk of neurodegenerative conditions.
According to data captured in the LevinPro HC database, this marks the 36th Laboratories, MRI and Dialysis transaction of 2026, and the 21st deal announced in the diagnostics specialty. Throughout all of 2025, there were 137 Laboratories, MRI and Dialysis transactions, 71 of which were in the diagnostic subsector.
